ISSN:2167-7964

Journal of Radiology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • OMICS J Radiol 2017, Vol 6(6): 281
  • DOI: 10.4172/2167-7964.1000281

Dendrimer-Trastuzumab Contrast Agent Improves Imaging of Magnetic Resonance Imaging (MRI) On Her2 Positive Breast Cancer Cell Line HCC-1954 in Apple Scaffold

Soekersi H1*, Bashari MH2, Huda F3, Rudiman R4, Sahiratmadja E5 and Soetikno RD1
1Department of Radiology, Faculty of Medicine, Dr. Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia
2Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
3Department of Anatomy, Physiology and Cellular Biology, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
4Department of Surgery, Faculty of Medicine, Dr. Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia
5Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
*Corresponding Author : Soekersi H, Department of Radiology, Faculty of Medicine, Dr. Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia, Tel: +6281221490629, Email: hsyabc47@gmail.com

Received Date: Nov 11, 2017 / Accepted Date: Nov 24, 2017 / Published Date: Nov 30, 2017

Abstract

Background: Gd-DOTA is a micromolecular compound that is not specific for HER2+ breast cancer cells. It is not retained in the tissues and easily excreted via kidney and stool leading to suboptimal imaging. Conjugation of Gd-DOTA with trastuzumab by dendrimer will create a macromolecule and specifically bind to HER2 receptor. This study aimed to evaluate enhancing intensity of Gd-Dota-Dendrimer-Trastuzumab by Magnetic Resonance Imaging (MRI) in HER2+ breast cancer cells HCC1954 in apple scaffold.

Methods: HER2+ breast cancer cell, HCC-1954 was culture in 3 dimensional culture system using apple scaffold. Intensity of contrast agents were evaluated using MRI. Cytotoxic activity of Gd-Dota-Dendrimer-Trastuzumab was evaluated in HER2+ breast cancer cells (HCC-1954 and SKBR-3) and HER2- breast cancer cell (MCF-7) using MTT assay. This study was an experimental test using Generalized Estimating Equation (GEE) method with statistical test of Generalized Linear Model (GLM) with exchangeable matrix correlation structure.

Result: We confirmed that HCC-1954 cells were grown in apple scaffold and increased intensity of MRI image. Interestingly, Gd-Dota-Dendrimer-Trastuzumab tended to increase intensity of MRI image compared to Gd-Dota using HCC-1954 cells in apple scaffold, although the difference was not significant (p>0.05). Importantly, the HER2+ sensitive to trastuzumab cells, SKBR3 cells were still sensitive to Gd-Dota-Dendrimer-Trastuzumab but not the HCC-1954 and MCF-7 cells.

Conclusion: Gd-Dota-Dendrimer-Trastuzumab was potentially increase MRI intensity in HER2+ breast cancer cells.

Keywords: Apple scaffold; HER2+ breast cancer; Gd-DOTADendrimer-Trastuzumab; Magnetic Resonance Imaging (MRI)

Citation: Soekersi H, Bashari MH, Huda F, Rudiman R, Sahiratmadja E, et al. (2017) Dendrimer-Trastuzumab Contrast Agent Improves Imaging of Magnetic Resonance Imaging (MRI) On Her2 Positive Breast Cancer Cell Line HCC-1954 in Apple Scaffold. OMICS J Radiol 6: 281. Doi: 10.4172/2167-7964.1000281

Copyright: ©2017 Soekersi H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top